Girentuximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Girentuximab
Monoclonal antibody
Type Whole antibody
Source Chimeric
Target CA-IX
Clinical data
Trade names Rencarex
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6460H10006N1718O2018S48
Molar mass 146.5 kg/mol
 NYesY (what is this?)  (verify)

Girentuximab (trade name Rencarex) is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX).[1] CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma.[2] Its development was suspended during phase III trials due to efficacy.[3][4]

Girentuximab was developed by Wilex AG. It was granted fast track status and orphan drug designation by the FDA for renal cancer.[5]

It triggers antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.[6]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Girentuximab" (PDF). American Medical Association. 
  2. ^ Bedke J, Stenzl A (2013). "Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?". Expert Review of Anticancer Therapy. 13 (12): 1399–408. PMID 24215158. doi:10.1586/14737140.2013.856761. 
  3. ^ https://clinicaltrials.gov/ct2/show/NCT00087022?term=girentuximab&rank=6
  4. ^ http://www.fiercebiotech.com/r-d/cyclacel-s-cancer-drug-isn-t-working-phase-iii-but-won-t-stop-trial
  5. ^ adisinsight.springer.com/drugs/800006571
  6. ^ Girentuximab (Rencarex) for renal cell carcinoma